GICS Sector : Healthcare
Standard BioTools Inc.creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide.It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology.
Standard BioTools reported a mixed bag in its Q1 2025 earnings, with revenues of $40.8 million, a 10% year-over-year decline, aligning with expectations but reflecting broader macroeconomic headwinds. Gross margin stood at 53.2% on a non-GAAP basis, feeling the pinch from tariffs and an unfavorable product mix. The company posted a net loss of $26 million, or -$0.07 per share, slightly missing the consensus estimate of -$0.04. Despite the top-line pressures, the company’s disciplined cost-cutting measures shone through, with non-GAAP operating expenses down 22% year-over-year to $38.6 million.
Publication Date: May -07
The quarter highlighted the company’s growing momentum in proteomics, with SomaScan making notable strides. As CEO Michael Egholm noted, "SomaScan demonstrated superior biomarker detection in studies on prostate cancer and lung complications from cancer treatment," underscoring its potential in precision medicine. Instrument sales, particularly for the Hyperion XTi, showed strength, with a 24% year-over-year increase to $7.8 million. However, consumables and services revenue both declined 16%, reflecting softer demand in academia. The launch of new products, including single SOMAmer agents and SomaScan 3.7K Select Asset, positions the company well for future growth.
Standard BioTools continued its aggressive cost-reduction efforts, slashing an additional $10 million in Q1, bringing total 2024 reductions to $80 million. These measures, combined with synergies from the SomaLogic integration, contributed to a 29% improvement in adjusted EBITDA loss to $16.9 million. The company’s cash position remains robust at $261 million, with no material debt, providing ample flexibility to invest in strategic initiatives. Free cash flow burn also improved, down 33% to $31 million, reflecting the efficacy of its restructuring efforts.
Trading at a P/S ratio of 2.11 and EV/EBITDA of -1.79, the stock appears to reflect the current challenges but also the potential for recovery. The company’s healthy cash reserves and disciplined cost management suggest it is well-positioned to navigate the near-term macroeconomic turbulence. With analyst estimates pointing to a 12.8% revenue growth next year, the market will closely watch whether Standard BioTools can execute on its strategic priorities, particularly in scaling its high-margin consumables business and leveraging partnerships like the one with Illumina.
First Look: CME outage, Black Friday shifts, AI job impact
Nov -28
Market Today: Stocks Rally, Tesla Robotaxi and Nvidia Scrutiny
Nov -26
Molecular Instruments and Standard BioTools Announce Collaboration to Bring Amplified Multi-Omic Readouts to Imaging Mass Cytometry
Nov -19
Illumina® Protein Prep delivers groundbreaking precision in NGS proteomics for more than 40 customers, ranging from academic institutions to large national biobanks
Nov -10
Standard BioTools Reports Third Quarter 2025 Financial Results
Nov -04
Standard BioTools to Announce Third Quarter Financial Results on November 4, 2025
Oct -21
Illumina® Protein Prep launches to drive greater proteomic insights for improved drug discovery and development
Sep -03
Standard BioTools (LAB) Reports Q2 Loss, Tops Revenue Estimates
Aug -12
Strong demand for life science research tools, increasing adoption of genomics and proteomics, and expansion into new markets drive Consumables segment growth at Standard BioTools Inc. Additionally, strategic partnerships, innovative product launches, and operational efficiencies contribute to the 8.97% growth rate.
Standard BioTools Inc.'s 8.5% growth is driven by increasing adoption of its novel genomics analysis instruments in research institutions and pharmaceutical companies, coupled with expanding applications in precision medicine and liquid biopsy. Additionally, strategic partnerships and investments in emerging markets are fueling growth.
Standard BioTools Inc.'s 10.95% growth is driven by increasing demand for genomics and proteomics research, expansion into new markets, and strategic partnerships. Additionally, advancements in bioinformatics and analytics, coupled with growing investments in precision medicine, are fueling growth in the life sciences sector.
Standard BioTools Inc.'s 10.83% growth is driven by increasing demand for genomics and proteomics research, expansion into new markets, and strategic partnerships. Additionally, the company's innovative product offerings, such as its proprietary bioinformatics platform, have contributed to its growth. Furthermore, the growing need for personalized medicine and diagnostics has also fueled the company's revenue growth.
Standard BioTools Inc.'s microfluidics products enable precise control over fluid flow, temperature, and other parameters, allowing for advanced biological and chemical analysis.
Standard BioTools Inc.'s genomics analysis products provide comprehensive genomic data analysis, interpretation, and reporting solutions.
Standard BioTools Inc.'s protein analysis products offer advanced tools for protein identification, quantitation, and characterization.
Standard BioTools Inc.'s cell analysis products provide high-resolution imaging and analysis solutions for cell biology research.
Standard BioTools Inc.'s nucleic acid purification products offer high-quality DNA and RNA purification kits and instruments.
Standard BioTools Inc.'s bioprocessing products provide scalable and efficient solutions for biologics manufacturing.
The threat of substitutes for Standard BioTools Inc. is moderate due to the availability of alternative products and services in the market.
The bargaining power of customers is high due to the presence of large and established customers who can negotiate prices and terms.
The bargaining power of suppliers is low due to the presence of multiple suppliers and the company's ability to negotiate prices.
The threat of new entrants is moderate due to the presence of barriers to entry, such as high capital requirements and regulatory hurdles.
The intensity of rivalry is high due to the presence of established competitors and the need to differentiate products and services.
| Value | |
|---|---|
| Debt Weight | 29.36% |
| Debt Cost | 4.62% |
| Equity Weight | 70.64% |
| Equity Cost | 12.16% |
| WACC | 9.95% |
| Leverage | 41.57% |
Value: 7.2
Growth: 4.0
Quality: 3.5
Yield: 0.0
Momentum: 10.0
Volatility: 1.7
1-Year Total Return ->
Value: 7.1
Growth: 1.7
Quality: 4.1
Yield: 2.0
Momentum: 7.0
Volatility: 3.3
1-Year Total Return ->
Value: 8.8
Growth: 1.0
Quality: 3.7
Yield: 7.0
Momentum: 0.0
Volatility: 1.3
1-Year Total Return ->
Value: 9.8
Growth: 4.7
Quality: 5.6
Yield: 0.0
Momentum: 0.5
Volatility: 0.0
1-Year Total Return ->
Value: 7.8
Growth: 3.6
Quality: 4.3
Yield: 0.0
Momentum: 1.5
Volatility: 1.3
1-Year Total Return ->
Value: 9.4
Growth: 0.9
Quality: 4.3
Yield: 0.0
Momentum: 1.0
Volatility: 0.0
1-Year Total Return ->